NCT05030155View on ClinicalTrials.gov

Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients with Eosinophilic Granulomatosis with Polyangiitis (E-merge)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 30, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Eosinophilic Granulomatosis with Polyangiitis
Interventions
DRUG

Mepolizumab

300 mg/month subcutaneous

DRUG

cyclophosphamide/azathioprine

Patients with FFS≥1 will receive cyclophosphamide then azathioprine

DRUG

Placebo

Patients with FFS=0 will receive placebo

Trial Locations (1)

75014

"Service de Médecine Interne, Centre de référence Maladies systémiques et autoimmunes rares, en particulier Vascularites nécrosantes et Sclérodermies systémiques Hôpital Cochin", Paris

All Listed Sponsors
collaborator

French Vasculitis Study Group

OTHER

collaborator

URC-CIC Paris Descartes Necker Cochin

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER